Tailored Alzheimer’s Indication Let Lecanemab Avoid Stronger Safety Warning, REMS

Eisai says ‘narrow’ indication negated need for REMS on amyloid-related imaging abnormalities and hemorrhages in the brain. Unusual nature of accelerated approval and confirmatory trial timing means safety data from the Phase III is barely mentioned in label.